Evonik's Standalone Case Faces Its First Real Test on November 3

Evonik has drawn a line that investors would do well to study closely: it will talk to BASF, but it will not negotiate. The board's rejection of takeover talks over BASF's voluntary public offer leaves the group's go-it-alone strategy resting on a single near-term pillar — the quarterly statement scheduled for November 3, 2026, covering the third quarter of 2026.

That date now carries unusual weight. With the board refusing to engage on price, the Q3 figures become the first hard evidence of whether Evonik can justify its independence economically, or whether the rejection will look like a defensive posture without substance behind it.

A Channel Stays Open, a Negotiation Does Not

The distinction the board is making is narrow but deliberate. Evonik says it remains available for a purely informational and confidential exchange. That is not the same as takeover negotiations, and it does not signal any convergence on valuation. Contact is preserved; the strategic position is not surrendered.

For shareholders, the gap between those two things matters. A confidential conversation can convey information without resolving divergent price expectations or strategic priorities. Anyone valuing the stock solely off the offer price should weigh the risk that the bid never becomes a realized takeover price at all.

Should investors sell immediately? Or is it worth buying Evonik?

The market's initial verdict was negative. According to dpa-AFX, Evonik shares fell in pre-market trading following the news, and the limited offer of talks did nothing to soften that reaction.

The €24 Question

BASF is holding firm at €24.00 per Evonik share, a premium of roughly 39% to the unaffected closing price. Friday's close of €21.06 sits below the amount on the table — a gap that frames the offer against a lower market price but does not by itself imply a completed sale on those terms.

The bid itself has a history. Reuters reported on October 23 that BASF had raised its offer to €24 per share, citing two people familiar with the matter; at that point neither company had confirmed the sweetened bid. Evonik's statement now refers explicitly to the improved offer, which puts more than price in play — the board is setting its standalone development course directly against it.

BASF, for its part, met the rejection with incomprehension on Monday, according to Reuters, and pointed to commitments made for employees and sites. The judgment that the offer is attractive belongs to BASF; it is not the same as Evonik's own assessment.

No Blank Check on a Higher Bid

Investors should not treat a further increase as a foregone conclusion. BASF chief executive Markus Kamieth said on Wednesday, per Reuters, that the company would not pay an inflated price — any acquisition must create value for BASF shareholders. That statement puts a firm ceiling on the idea of an endlessly sweetened offer.

There is a second strand to the story, too. Roughly a week ago, Handelsblatt reported that Evonik was examining a larger acquisition in the United States and had set its sights on Ashland. No takeover agreement was indicated, so the review remains distinct from a binding transaction.

Evonik at a turning point? This analysis reveals what investors need to know now.

Two Paths From Here

The constructive scenario requires Evonik to back its independence with convincing business results. Should the upcoming numbers provide solid arguments, the debate could shift back toward operating performance, and the rejection would be judged on the business rather than read as pure defence. The willingness to exchange information would then look like a supplementary contact rather than a prerequisite for the investment case — no further increase in the offer would be needed.

The adverse scenario pairs disappointing figures with takeover talks that stay blocked. In that case the market may press harder on what economic advantage independence actually offers over the bid, and a reference to the company's own course would not offset weak operations.

Either way, the board's position is unambiguous until something changes: Evonik intends to stay independent, refuses takeover negotiations, and permits only a confidential flow of information. That opens a communication channel — not a negotiation process. The November 3 statement will not settle the takeover question on its own, but it can change the ground on which investors weigh Evonik's solo path against BASF's offer.

Ad

Evonik Stock: New Analysis - 31 October

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...